

CLINICAL TRIAL

NCT03913143 - ILLUMINATE

Pediatric Ophthalmology



A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber's Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate)

Rare Eye Disease concerned by the trial :
Leber Congenital Amaurosis

Status of the trial : Recruiting
Orphan drug recognition : No

Inclusion criteria : [click here to see detailed criteria](#)

Exclusion criteria : [click here to see detailed criteria](#)



Inclusion opening date: 04/2019



Inclusion closing date (previsional): 12/2020

Children



Adults



Within ERN-EYE members



Locations of the trial :

CHNO des XV XX - Centre Hospitalier National d'Ophthalmologie
Paris, France

Strasbourg University Hospital - CARGO
Strasbourg, France

Center for Ophthalmic Research, University of Tübingen
Tübingen, Germany




Principal investigators names :

Isabelle Audo (Paris)
Hélène Dollfus (Strasbourg)
Katarina Stingl (Tübingen)



Other investigators :
Saddek Mohand Saïd



Funder type : Industry

[More informations](#)